45 results about "Hypoxic ischemic" patented technology

The invention provides aporphine and oxoaporphine compounds that have endothelial nitric oxide synthase (eNOS) maintaining or enhancing activities and may be used to manufacture a medicaments for preventing or treating ischemic diseases in human and mammal, and the ischemic diseases may include ischemic cerebral apoplexy, ischemic cerebral thrombosis, ischemic cerebral embolism, hypoxic ischemic encephlopathy, ischemic cardiac disease or ischemic enteropathy etc.

The key obstacle for current resuscitation is the acutely limited time window. The major reason for the limited time window is that the brain and spinal cord are extremely vulnerable to hypoxic-ischemic insult. A method and a lymph-like fluid composition for resuscitation of cardiac arrest are provided. The method includes steps of inhibiting CSF production, removing CSF, replacing the CSF with invented lymph-like fluid composition plus conventional CPR. The lymph-like fluid composition includes polypeptides, insulin, elevated magnesium concentration and ATP in artificial CSF.

The invention belongs to pharmaceutical preparations containing protein materials. It is an oral preparation of intestinal trefoil factor, which is characterized in that it contains intestinal trefoil factor as a pharmacodynamic active component, and also contains intestinal trefoil factor activator and intestinal trefoil factor protective agent. It is clinically used for the treatment of gastrointestinal ischemia-hypoxic injury, such as peptic ulcer, radiation enteritis, chronic gastritis, enteritis and other diseases caused by various reasons, and can rapidly promote the proliferation of gastrointestinal epithelial cells, Stabilizes the gastrointestinal mucus layer, does not interfere with glucose metabolism and promote gluconeogenesis, and has no side effects of promoting the expression of bacterial drug resistance genes and promoting the growth of tumor cells.

The present invention designs and synthesizes the ascorbyl ester derivatives of the aryl (ethanoic) propanoic acid non-steroidal anti-inflammatory medicaments, such as ibuprofen, ketoprofen and naproxen, and addition salt of the derivatives with pharmaceutical acid or pharmaceutical alkaline. The non-steroidal anti-inflammatory medicament which takes the ibuprofen as the representative is a common antipyretic analgesic medicament. The invention has remarkable antipyretic and analgesic effects and good safety except for anti-inflammatory effect, thus being not only suitable for adults, but also suitable for the elderly people, infants and children. The aryl (ethanoic) propanoic acid ascorbyl ester can be converted into ascorbyl ester derivatives and the addition salts of the derivatives with pharmaceutical acid or pharmaceutical alkaline, which can improve the water solubility thereof, facilitate intravenously administration, reduce the onset time, improve the bioavailability, reduce the stimulation effect to gastrointestinal tract, and enhance the penetrating capacity to hemato encephalic barrier, and can be used as a novel medicament to be applied for antiphlogistic, antipyresis, analgesia, treatment of arthritis, dysmenorrheal, multiple sclerosis, pneumonia cystic fibrosis and patent ductus arteriosus of premature infants, and prevention and treatment of cerebral apoplexy, hypoxic-ischemic brain damage, senile dementia and certain cancers.

The present invention relates to the use of xenon in the preparation of a medicament for preventing and / or alleviating one or more anesthetic-induced neurological deficits in a neonatal subject.The present invention further relates to combinations of xenon and sevoflurane, and use thereof as preconditioning agents for administration prior to hypoxic-ischaemic injury.

The invention discloses a novel nerve protective agent, which belongs to the technical field of nerve protective medicine. The novel nerve protective agent comprises one kind or two kinds or three kinds of the following ingredients and contents: (1) antioxidants (with the dosage between 2.0 and 200 mg / kg); and (2) calcium ion antagonists (with the dosage between 1.0 and 400 mg / kg); and (3) adenosine diphosphate RNA polymerase inhibitors (with the dosage between 2.0 and 300 mg / kg). The invention carries out multi-blockage on the neurotrosis induced by free radicals in an acute phase of hypoxic-ischemic brain damage. Particularly, when three kinds of anti-oxygen free radicals-anti-inter-cell calcium ion overloading-PARP inhibitors are in combined use, the invention provides the protective effect on the acute phase damage of the ishemic stroke from multiple levels and multiple target points. Compared with a single protective agent, the compounded protective agent has stronger protective effect on both the in-vivo oxidative stress damage and the in-vitro oxidative stress damage of the ishemic stroke, and has good treatment effect on the hemorrhagic stroke.